stockrow
Friday 6 November 2026
Export TRLV’s income statement to Excel — free account
Trulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
11.54
0.64
+5.87%
Follow TRLV
Alert me
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 | 6 | 6 |
P/E ratio |
207.75 | 207.75 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 3.89 | 1.12 | 0.86 | 0.83 | 1.41 |
Altman Z-Score |
— | 2.37 | 1.08 | 0.42 | 0.70 | 0.98 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 6.63 | 8.21 | 7.98 |
Altman Z″-Score (non-manufacturers) |
— | 3.00 | 2.10 | 0.68 | 1.20 | 1.09 |
Beneish M-Score |
— | — | (3.02) | (3.46) | (1.79) | (2.99) |
P/Operating CF |
91.54 | (58.30) | 24.88 | 7.42 | 32.08 | 28.08 |
P/B ratio |
0.00 | 1.69 | 0.71 | 0.69 | 0.79 | 1.45 |
Price to Tangible BV |
0.00 | 12.05 | 9.04 | 129.72 | 0.00 | 0.00 |
EV/Sales |
0.00 | 4.21 | 1.53 | 1.16 | 1.04 | 1.44 |
EV/EBITDA |
0.00 | 13.91 | 7.89 | 0.00 | 4.65 | 5.36 |
EV/Operating CF |
0.00 | 304.42 | 80.56 | 6.48 | 4.53 | 6.23 |
EV/FCF |
0.00 | (16.88) | (11.70) | 8.90 | 10.25 | 8.15 |
Quick Ratio |
— | 1.43 | 1.05 | 1.87 | 2.30 | 2.16 |
Current Ratio |
— | 3.10 | 2.82 | 4.16 | 4.37 | 4.43 |
Net Debt/EBITDA |
0.00 | 1.07 | 2.09 | (6.53) | 0.93 | 0.11 |
Debt/Assets |
— | 15.67% | 20.76% | 19.81% | 18.97% | 10.82% |
Debt/Equity |
— | 0.25 | 0.37 | 0.38 | 0.44 | 0.26 |
Asset Turnover |
0.00 | 0.00 | 0.36 | 0.37 | 0.42 | 0.42 |
Operating CF/Net income |
1.58 | 0.72 | (0.09) | (0.38) | (1.75) | (2.34) |
Capex/Depreciation |
(4.70) | (3.14) | (0.99) | (0.30) | (0.89) | (0.35) |
Interest Coverage |
10.79 | 7.01 | 0.68 | (2.72) | 1.57 | 2.26 |
| 0.00% | 0.00% | (12.08%) | (31.58%) | (11.67%) | (9.73%) | |
| 0.00% | 0.00% | (7.22%) | (17.19%) | (5.54%) | (4.18%) | |
ROIC |
0.00% | 5.21% | 1.30% | (7.95%) | 4.09% | 7.61% |
Return on Tangible Assets |
0.00% | 1.59% | (21.84%) | (50.71%) | (13.12%) | (10.52%) |
Average Days of Receivables |
0.00 | 3.37 | 1.95 | 2.17 | 5.63 | 5.86 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
29.81% | 33.41% | 36.70% | 34.20% | 43.02% | 37.69% |
Intangible Assets out of Total Assets |
0.00 | 0.54 | 0.52 | 0.51 | 0.47 | 0.48 |
Share Based Compensation of Revenue |
0.53% | 0.99% | 1.49% | 0.94% | 1.70% | 1.73% |
Graham Net Nets |
0.00 | (0.20) | (0.64) | (0.86) | (1.03) | (0.60) |
Graham Number |
0.00 | 6.59 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
0.48% | 0.48% | (18.46%) | (54.67%) | (16.31%) | (7.16%) |
Free Cash Flow Yield |
0.00% | (6.42%) | (11.62%) | 15.08% | 12.18% | 12.53% |
Revenue per Share |
4.59 | 6.69 | 6.48 | 5.98 | 6.24 | 6.17 |
Operating CF per Share |
0.88 | 0.09 | 0.12 | 1.07 | 1.43 | 1.43 |
Capex per Share |
(1.25) | (1.76) | (0.98) | (0.27) | (0.78) | (0.32) |
Free Cash Flow per Share |
(0.37) | (1.67) | (0.86) | 0.80 | 0.65 | 1.11 |
Cash per Share |
0.00 | 1.67 | 1.14 | 1.10 | 1.58 | 1.34 |
Shareholders Equity per Share |
0.00 | 15.41 | 10.25 | 7.45 | 6.57 | 5.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 15.41 | 10.25 | 7.45 | 6.57 | 5.97 |
Free Cash Flow |
(42.28) | (232.66) | (160.92) | 150.99 | 123.82 | 212.31 |
Working Capital |
— | 355.48 | 383.25 | 362.50 | 466.07 | 435.77 |
Capital Expenditures |
(141.93) | (245.56) | (184.02) | (50.85) | (147.66) | (60.51) |
Net Current Asset Value |
— | (739.08) | (879.16) | (843.09) | (1,016.68) | (990.37) |
EV/EBIT |
0.00 | 19.24 | 37.09 | 0.00 | 12.56 | 11.84 |
Capex to Sales |
0.27 | 0.26 | 0.15 | 0.05 | 0.12 | 0.05 |
Price to Operating Income |
0.00 | 17.76 | 27.28 | 0.00 | 10.07 | 11.59 |
| Other line items | ||||||
Depreciation/Fixed assets |
0.00 | 0.10 | 0.25 | 0.25 | 0.23 | 0.26 |
Cash ROIC |
0.00% | (7.98%) | (5.65%) | 7.00% | 5.91% | 12.56% |
Accounts Receivable Turnover |
0.00 | 0.00 | 161.27 | 170.96 | 94.92 | 63.42 |
Accounts Payable Turnover |
0.00 | 0.00 | 6.02 | 6.55 | 5.31 | 5.32 |
Inventory Turnover |
0.00 | 0.00 | 2.18 | 2.21 | 2.12 | 1.98 |
Average Days of Payables |
0.00 | 93.71 | 56.58 | 56.15 | 72.91 | 64.19 |
Days of Inventory on Hand |
0.00 | 209.74 | 190.75 | 143.90 | 179.40 | 188.16 |
Average Receivables |
— | — | 7.55 | 6.61 | 12.50 | 18.63 |
Average Payables |
— | — | 87.91 | 82.59 | 88.60 | 88.35 |
Average Inventory |
— | — | 243.22 | 244.81 | 222.25 | 236.83 |
Average Assets |
— | — | 3,405.89 | 3,064.73 | 2,799.66 | 2,783.18 |
Average Common Equity |
— | — | 2,037.54 | 1,668.16 | 1,328.82 | 1,196.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026